Advancing the Diagnosis and Treatment of Rare Primary Immune Disorders

推进罕见原发性免疫性疾病的诊断和治疗

• 批准号: 10250420
• 负责人: SUNG-YUN PAI
• 金额: $ 1.1万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-12 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10250420
• 关键词: Address; Affect; American; Award; B-Lymphocytes; Biological; Biology; Blood; Bone Marrow; Boston; Cell physiology; Cells; Child; Clinical; Clinical Data; Clinical Protocols; Clinical Research; Clinical Research Protocols; Clinical Trials; Collaborations; Collection; DNA; Data; Diagnosis; Diagnostic; Disease; Early Diagnosis; Enrollment; Fibroblasts; Funding; Future; Genetic; Genetic Diseases; Goals; Grant; Immune; Immune System Diseases; Infant; Innovative Therapy; Institutional Review Boards; Intervention; Leadership; National Institute of Allergy and Infectious Disease; Outcome; Patients; Pediatric Hospitals; Phenotype; Pilot Projects; Process; Productivity; Protocols documentation; Publications; Rare Diseases; Research; Research Personnel; Research Project Grants; Sampling; Site; Skin; Specimen; T-Lymphocyte; Time; Translations; Treatment outcome; Universities; clinical database; clinical trial readiness; conditioning; congenital immunodeficiency; data infrastructure; design; evidence base; exhaustion; immunoregulation; innovation; insight; meetings; novel; pre-clinical assessment; preclinical study; programs; success

PIDTC PILOT/FEASIBILITY CORE SUMMARY/ABSTRACT The Primary Immune Deficiency Treatment Consortium (PIDTC) was established in 2009 as a collaboration among North American centers with expertise in treating infants and children with rare, but serious primary immunodeficiencies (PIDs). In this application, we propose a clinical research project examining a group of newly described disorders, the Primary Immune Regulatory Disorders (PIRD, Project 6906), which extends the scope of PIDTC to encompass genetic disorders affecting immune regulation. The Pilot/Feasibility Core has funded 7 projects in its lifetime, 4 in the past cycle. These annual $50,000 awards are granted after rigorous review for scientific merit, prioritizing projects that have the potential to impact the field, leverage data and infrastructure of the RDCRN and PIDTC, and have a high likelihood of translation to clinical trials. Investigators wishing to receive a 2nd year of funding are reviewed in a competitive renewal process that puts emphasis on demonstration of meeting milestones stated in the application. In this application, we plan to continue our successful and productive Pilot program, transitioning the leadership to Dr. Sung-Yun Pai, to fulfill Specific Aim 1: To select and fund timely innovative research in PID and its treatment which in turn results in tangible outcomes that advance the goals of PIDTC and fuel clinical trial readiness. Notwithstanding our successes to date, we have recognized that implementation of funded Pilot studies using data and samples acquired in the context of the clinical research projects has been slow. For future Pilot projects, we will pursue Specific Aim 2: To use a PIDTC-specific, consortium-wide, biological sampling and sharing protocol to facilitate rapid implementation of Pilot/Feasibility Core supported studies and other studies relying on samples from patients. Through these specific aims, we hope to broaden the success we have had leveraging clinical research protocol and Pilot project data in SCID to develop and launch an evidence-based clinical trial in SCID (Conditioning SCID Infants Diagnosed Early, CSIDE study, NCT03619551) to other PID and PIRD.

PIDTC试点/可行性核心 总结/摘要 原发性免疫缺陷治疗联盟（PIDTC）成立于2009年， 在北美的中心，在治疗婴儿和儿童罕见的，但严重的主要 免疫缺陷（PID）。在本申请中，我们提出了一个临床研究项目，检查一组 新描述的疾病，原发性免疫调节障碍（PIRD，项目6906），它扩展了免疫调节障碍的范围。 PIDTC的范围包括影响免疫调节的遗传性疾病。试点/可行性核心 在其存在期间资助了7个项目，在上一个周期资助了4个项目。这些每年5万美元的奖项是经过严格的 审查科学价值，优先考虑有可能影响该领域的项目，利用数据， RDCRN和PIDTC的基础设施，并有很高的可能性转化为临床试验。调查人员 希望获得第二年资助的人在竞争性更新过程中进行审查，重点是 证明申请书中所述的会议里程碑。在这个应用程序中，我们计划继续我们的 成功和富有成效的试点计划，将领导权移交给派博士，以实现特定目标 1：选择并资助及时的PID及其治疗创新研究，从而产生有形的 结果，推进PIDTC的目标和燃料临床试验准备。尽管我们取得了成功， 迄今为止，我们已经认识到，利用在 临床研究项目进展缓慢。对于未来的试点项目，我们将追求具体目标2： 使用PIDTC特定的、全联盟范围的生物采样和共享协议来促进快速 实施试点/可行性核心支持的研究和其他依赖于患者样本的研究。 通过这些具体目标，我们希望扩大我们利用临床研究取得的成功 SCID的方案和试点项目数据，以开发和启动SCID循证临床试验 （早期诊断的条件性SCID婴儿，CSIDE研究，NCT 03619551）与其他PID和PIRD。